2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2258

Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials
Abstract Number: 1077

Less Time Spent In Sedentary Behavior Is Associated With Better Future Physical Function: Objective Data From The Osteoarthritis Initiative
Abstract Number: 844

Level and Determinants Of Health Related Quality Of Life In Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 507

Level Of Agreement Of The AECG 2002 and ACR 2012 Classification Criteria For Sjögren’s Syndrome In The Brittany Cohort: Clues To Understand Discrepancies
Abstract Number: 480

Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Abstract Number: 2307

Lifestyle Factors Were Seldom Discussed With Patients Visiting a Rheumatology Clinic
Abstract Number: 1152

Ligation Of TLR5 Promotes Myeloid Cell Infiltration and Differentiation Into Mature Osteoclasts In RA Patients and Experimental Arthritis
Abstract Number: 1581

Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
Abstract Number: 657

Lipoic Acid Plays a Crucial Role In Scleroderma Dermal Fibroblasts
Abstract Number: 1987

LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS
Abstract Number: 725

Localization At The Immunological Synapse Of Adaptor Protein Grb2 and PLC Gamma-1 In Non-Stimulated Peripheral Blood T Lymphocytes From Patients With Systemic Lupus Erythematosus Suggests An In Vivo dysregulated Activation State
Abstract Number: 2872

Long Noncoding RNA Nron Regulates The Cytoplasmic-Nuclear Shuttling and Activity Of NFAT5 In Rheumatoid Arthritis Synovial Fibroblast
Abstract Number: 2045

Long QT and Hydroxychloroquine; A Poorly Recognised Problem In Rheumatology Patients
Abstract Number: 2466

Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Abstract Number: 2509

Long Term Natural History Of Asymptomatic Avascular Necrosis In a Cohort Of Patients With Systemic Lupus Erythematosus Treated With Corticosteroids

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].